Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Online Resource  (448)
  • American Association for Cancer Research (AACR)  (448)
  • Medicine  (448)
Type of Medium
  • Online Resource  (448)
Publisher
  • American Association for Cancer Research (AACR)  (448)
Language
Years
Subjects(RVK)
  • Medicine  (448)
RVK
  • 1
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Research Vol. 75, No. 15_Supplement ( 2015-08-01), p. 2474-2474
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 2474-2474
    Abstract: Elevated serum levels of the small integrin binding ligand N-linked glycoprotein (SIBLING) family member bone sialoprotein II (BSP) have been related to breast cancer skeletal metastasis. Also, knockdown of BSP was associated with significant anti-proliferative, anti-migratory and anti-clonogenic effects in MDA-MB-231 human breast cancer cells, and rats presenting with osteolytic metastases following femoral artery injection of these cells underwent complete remission following BSP knockdown, thus validating BSP as target. In order to follow a translational perspective, we used the IDK-1 rat monoclonal antibody against BSP (Immundiagnostik, Bensheim, Germany) for treating MDA-MB-231 cells in vitro and in vivo. MDA-MB-231 cells were exposed to IDK-1 for assessing its effect on proliferation and migration. The presence of BSP in the cytosol and on cell membranes was checked by FACS analysis. In addition, the location of BSP was investigated by immunocytochemistry. For in vivo experiments, 1×105 MDA-MB-231luc breast cancer cells were injected into the femoral artery of male nude rats with skeletal lesions developing subsequently in the respective hind leg. A preventive arm based on pretreated rats and / or MDA-MB-231 cells was compared with a treatment arm, in which antibody administration (10 mg/kg/week) started when tumor bearing rats had shown stable tumor growth. The appearance and growth of soft tissue tumors was monitored by luciferin induced light emission and recorded by a Xenogen IVIS 100 imaging system. Concomitant skeletal lesions were detected by CT scans. Tumors as well as skeletal lesions were subjected to pathohistological evaluation by hematoxylin and eosin staining as well as immunohistochemical staining for BSP. There was no effect of the anti-BSP antibody IDK-1 on the proliferation or migration of MDA-MB-231 cells. In line with this, FACS analysis revealed only low concentrations of BSP in MDA-MB-231 cells growing in vitro. Immunocytochemical staining for BSP showed that this SIBLING protein could be detected only in a minority of the MDA-MB-231 cells. However, when treating nude rats bearing fully established MDA-MB-231 tumors, administration of the IDK-1 antibody caused complete remissions in 80% of treated rats (10mg/kg/week for 6 weeks). When pre-treating the nude rats, however, and / or pre-exposing the MDA-MB-231 cells to IDK-1 in addition to treating the established tumors, the above mentioned effect could not be increased. Interestingly, histological evaluation of serial sections of MDA-MB-231 tumors growing in nude rats showed a very robust expression and vesicular secretion of BSP. It is concluded, that the in vivo growth of MDA-MB-231 cells is associated with dramatically increased expression and secretion of BSP, which then is a valid target for the anti-BSP antibody, leading to complete remissions of MDA-MB-231 tumors in nude rats. Citation Format: Michael Zepp, Irina Berger, Heidegard Hilbig, Franz-Paul Armbruster, Martin R. Berger. A rat monoclonal antibody against bone sialoprotein II shows differential activity in MDA-MB-231 cells growing in vitro or in vivo. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2474. doi:10.1158/1538-7445.AM2015-2474
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4352-4352
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4352-4352
    Abstract: Erufosine is a new antineoplastic agent from the class of alkylphosphocholines, which interferes with AKT phosphorylation, the related signal transduction and confers apoptosis. An improved understanding of its mode of action is important for its potential clinical application. The present study demonstrates that erufosine's antileukemic efficacy is related to the level of cellular retinoblastoma (Rb) protein expression. Stable Rb-knockdown in SKW-3 leukemia T-cells was induced by lentiviral delivery of constructs expressing short-hairpin-RNA species with 21 or 27 bp lengths. The cytotoxicity of erufosine was tested via MTT proliferation test on thus engineered cell populations with reduced Rb expression levels. Likewise, the clonogenicity of these engineered cell populations was determined by CFU assay before and after treatment with erufosine. The effects on cell cycle were investigated by FACS analysis. The expression of signal transduction factors was examined by RT-PCR and immunoblot. The Rb protein expression levels in the shRNA-transduced cells ranged from 1%- 36% of wild type or nonsense control. Low Rb expression correlated with significantly diminished antiproliferative and anticlonogenic activities of erufosine (p & lt;0.05) at concentrations near and above the IC50. Erufosine induced a G2 arrest, and complete Rb-deficiency aggravated this condition. With regard to proteins involved in cell cycle and apoptosis induction, Rb-deficiency reduced the expression of cyclin D3, that of the subsequently regulated kinase Cdk 4 and activated caspases 3 and 9, followed by PARP-cleavage. In partial variance, erufosine reduced cyclin D3 at RNA and protein levels, but affected not or only slightly the expression of its partner kinase Cdk 4. Rb-knockdown impaired the cytotoxic effect of erufosine significantly and contributed to the formation of a resistant cell fraction. It is concluded that Rb is a main mediator of erufosine's antileukemic activity and this suggests that the effect of the drug in patients might be predicted by determining the Rb expression status. Citation Format: Maya M. Zaharieva, Milen Kirilov, Minquang Chai, Stefan M. Berger, Spiro M. Konstantinov, Martin R. Berger. Down regulation of retinoblastoma protein expressionimpedes the antileukemic activity of erufosine. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4352. doi:10.1158/1538-7445.AM2013-4352
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2614-2614
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2614-2614
    Abstract: Breast cancer is a leading cause of cancer related death in women due to onset of metastasis. Bone metastasis is the most frequent complication occurring in patients with advanced breast cancer and bone sialoprotein (BSP) is related to this process. However, the underlying mechanisms are not clear yet. Therefore, the aim of the study was to analyze BSP functions in greater detail and to decipher its signaling pathways contributing to bone metastasis. To that purpose a combination of the tetracycline-controlled transcription activation system (“Tet-Off system”) and RNA interference was used to initiate and maintain the conditional knockdown of BSP for any intended period. This new technique was established in MDA-MB-231 subclones by recombinase-mediated cassette exchange. Additionally, the cell clones were equipped with the reporter genes mCherry and firefly luciferase for testing their regulative properties and following their fate. In absence of doxycycline, the expression of a miRNA targeting BSP was activated and after six days of BSP knockdown the ensuing cellular, metastatic or molecular properties were monitored by fluorescent microscopy, flow cytometry analysis, assays for proliferation, migration and colony formation, as well as expression profiling analysis. Furthermore, the cell clones were examined in a nude rat model for soft tissue and osteolytic lesions after 2 to 6 weeks of miRNA treatment. The clones revealed good regulative properties to doxycycline. Phenotypic changes indicating apoptosis were observed after 6 days of conditional knockdown which was characterized by up to 86% decreased BSP levels and resulted in significant anti-proliferative, anti-migratory and anti-clonogenic effects in vitro. Additionally, the effect of miRNA-mediated BSP knockdown was assessed in vivo. Significant decreases (p & lt; 0.03) and even complete remissions of soft tissue and osteolytic lesions were found following 3 and 6 weeks of miRNA treatment by bioluminescence and magneting resonance imaging, as well as volume computed tomography. The microarray data showed modulated expression in 1.3% of all genes, thus hinting to specific effects in response to BSP knockdown. These genes included increased expression of endoplasmic reticulum stress and apoptosis related genes (ATF3, CHOP), of transcription factor c-FOS, of the gene related to breast epithelial differentiation (ID2) and the tumor suppressor gene EGR1. Conversely, there was suppression of metastasis associated genes (CD44, IL11). These findings were confirmed by western blot for induction of intrinsic and extrinsic apoptotic pathways as shown by cleavage of caspases 8, 9, 3 and 7, and of PARP, as well as the upregulation of ATF3, DDIT3 (CHOP), c-FOS, ID2 and CD44. In conclusion, the role of BSP in the development of skeletal metastasis has been defined more precisely and renders this protein an attractive target in the treatment of this disease. Citation Format: Marineta Kovacheva, Michael Zepp, Stefan Berger, Martin R. Berger. Bone sialoprotein is an essential target in breast cancer skeletal metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2614. doi:10.1158/1538-7445.AM2014-2614
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 4_Supplement ( 2017-02-15), p. P2-04-23-P2-04-23
    Abstract: The SIBLING protein bone sialoprotein II (BSP) has been implicated in lytic skeletal metastasis as it is expressed in a subset of primary breast cancers and can be detected at elevated levels in the serum of patients with increased risk to develop skeletal metastasis. The aim of this study was to investigate the potential application of a rat monoclonal antibody against hypo-glycosylated BSP (IDK1) for diagnostic and therapeutic purposes. The diagnostic part of this study was based on breast cancer specimens from the biobank / repository of the Institute of Pathology of the Municipal Hospital Kassel, Germany. Immune-histochemical analyses were performed with IDK1 for comparing BSP expression between ten human primary breast tumor sections and their corresponding bone metastatic tissue samples. The therapeutic part of this study was based on a model in nude rats, in which the rats were implanted with human MDA-MB-231 breast cancer cells for selective and orthotopic appearance of osteolytic skeletal lesions. Tumor bearing rats were treated with IDK1 starting at two or four weeks after tumor cell inoculation into the femoral artery of one hind leg. Tumor growth was monitored by light emission, caused by luciferase mediated metabolism of luciferin. Photon emission was recorded at regular intervals by a Xenogen IVIS 100 imaging system. After sacrifice, samples of lesions and apparently healthy tissues were investigated by H & E staining as well as by immune-histological staining for BSP. BSP staining was found within the cytoplasm of tumor cells. Increased expression of BSP was also detected in healthy bone cells, e.g. osteoblasts, as soon as breast tumor cells invaded bone tissue. An elevation of BSP expression near necrotic centers was also found. Expression of BSP in primary breast tumors was positively correlated with BSP expression in bone metastases. Furthermore, bone metastases showed higher and more intensive expression of BSP than their respective primary breast tumors (p & lt;0.0039). In the experimental treatment part, all but one untreated tumor bearing rats showed rapid tumor growth accompanied with lytic destruction of femur and tibia of the respective hind leg (18/19; tumor take rate 95%). In contrast, rats treated with the anti-BSP antibody did not show a significant increase in light emission nor a clinical deterioration. In fact, 8 of 10 rats receiving the antibody at a dose of 10 mg/kg/week starting at two weeks after tumor implantation did not show any light emission after 4 to 6 weeks (p = 0.01 versus control) as well as 6 of 10 rats receiving the antibody at the same dose starting at four weeks after tumor implantation (p & lt; 0.05). Radiological and histological examination confirmed that animals without light emission were free of tumor growth, corresponding to a complete remission. In conclusion, the rat monoclonal antibody directed against BSP is a powerful tool with potential for diagnostic and therapeutic applications in breast cancer skeletal metastasis and warrants further development. Citation Format: Berger MR, Zepp M, Westphal G, Berger I, Armbruster FP. A monoclonal antibody against hypo-glycosylated bone sialoprotein II has application for diagnostic purposes in samples of breast cancer patients and for treatment of skeletal metastasis caused by MDA-MB-231 breast cancer cells in rats [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-23.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2750-2750
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2750-2750
    Abstract: Microtubuli-associated proteins could be potent novel targets for anti-cancer therapy. To test this hypothesis, a HeLa cell line was generated, in which the reverse tetracycline-dependent transactivator rtTA2S-M2 drives the expression of eGFP and a miRNA, inducing RNAi-dependent inhibition of TPX2 expression, from the bidirectional tet-regulated promoter (HeLa EM2-11-TPX2). As a negative control for respective experiments a similar cell line was generated (HeLa EM2-11), in which the presence of the inducer doxycycline (dox) activates expression of the genes mCherry and firefly luciferase. First, the effect of TPX2 knockdown on in vitro proliferation was determined by MTT assay. Here, the respective cells were treated with either a single agent therapy consisting of vincristine (VC) (0.5-2.6 ng/ml) or docetaxel (DCX) (0.125-4 nmol/l) or dox (0.2 μg/ml), or a combination of dox and VC or DCX, and cell viability was assessed after 72h. Treatment with VC or DCX caused a concentration-dependent decrease in proliferation in vitro, whereas knockdown of TPX2 reduced cell growth by 35-45%. The proliferation of HeLa EM2-11-TPX2 was synergistically reduced by the combination treatment dox and VC and additively reduced by dox and DCX when compared to the single agent exposures. Next, the efficiency of tumor growth inhibition following knockdown of TPX2 alone or in combination with VC or DCX was tested in a nude mouse xenograft model. Here, the size of tumors growing in nude mice following s.c. implantation was monitored over a period of 4-5 weeks. Dox (0.2 mg/ml in drinking water) was given continuously from day 14 after cell injection until the end of the observation period. The antimitotic agents VC (1 mg/kg) or DCX (22.3 mg/kg) were applied twice on days 14 and 21. In nude mice, TPX2-knockdown alone caused a 71% reduction in tumor growth. VC or DCX reduced tumor growth by 59% or 76%, respectively. The combination of dox and VC or DCX inhibited tumor growth by 93% or 97%, respectively. Both combination treatments were significantly superior to the respective single treatment arms (p & lt;0.05). We could demonstrate that persistent inactivation of TPX2 expression was highly effective in inhibiting tumor growth, both in vitro and in vivo. The combination of the conditional TPX2-knockdown and VC showed a synergistic therapeutic effect in vitro, whereas the combination of TPX2-knockdown and DCX showed an additive therapeutic effect in vitro. Both combination treatments were significantly superior to the respective single agent treatments in vivo. It is concluded that TPX2 is a valuable treatment target, causing effective tumor growth inhibition, which can be successfully combined with other anti-mitotic agents. Citation Format: Annette J. Allmendinger, Kai Schönig, Oliver J. Gruss, Stefan Berger, Martin R. Berger. Conditional RNAi-mediated knockdown of TPX2 synergizes with vincristine and docetaxel cytotoxicity against HeLa cell sub-clones in vitro and in vivo. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2750. doi:10.1158/1538-7445.AM2014-2750
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 23, No. 2 ( 2017-01-15), p. 466-477
    Abstract: Purpose: The identification and vetting of cell surface tumor-restricted epitopes for chimeric antigen receptor (CAR)–redirected T-cell immunotherapy is the subject of intensive investigation. We have focused on CD171 (L1-CAM), an abundant cell surface molecule on neuroblastomas and, specifically, on the glycosylation-dependent tumor-specific epitope recognized by the CE7 monoclonal antibody. Experimental Design: CD171 expression was assessed by IHC using CE7 mAb in tumor microarrays of primary, metastatic, and recurrent neuroblastoma, as well as human and rhesus macaque tissue arrays. The safety of targeting the CE7 epitope of CD171 with CE7-CAR T cells was evaluated in a preclinical rhesus macaque trial on the basis of CD171 homology and CE7 cross reactivity. The feasibility of generating bioactive CAR T cells from heavily pretreated pediatric patients with recurrent/refractory disease was assessed. Results: CD171 is uniformly and abundantly expressed by neuroblastoma tumor specimens obtained at diagnoses and relapse independent of patient clinical risk group. CD171 expression in normal tissues is similar in humans and rhesus macaques. Infusion of up to 1 × 108/kg CE7-CAR+ CTLs in rhesus macaques revealed no signs of specific on-target off-tumor toxicity. Manufacturing of lentivirally transduced CD4+ and CD8+ CE7-CAR T-cell products under GMP was successful in 4 out of 5 consecutively enrolled neuroblastoma patients in a phase I study. All four CE7-CAR T-cell products demonstrated in vitro and in vivo antitumor activity. Conclusions: Our preclinical assessment of the CE7 epitope on CD171 supports its utility and safety as a CAR T-cell target for neuroblastoma immunotherapy. Clin Cancer Res; 23(2); 466–77. ©2016 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 26, No. 14 ( 2020-07-15), p. 3819-3830
    Abstract: Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate whether activating mutations in the telomerase reverse transcriptase (TERT) gene promoter are present in MPM and associated with disease progression, cell immortalization, and genomic alteration patterns. Experimental Design: TERT promoters were sequenced in 182 MPM samples and compared with clinicopathologic characteristics. Surgical specimens from 45 patients with MPM were tested for in vitro immortalization. The respective MPM cell models (N = 22) were analyzed by array comparative genomic hybridization, gene expression profiling, exome sequencing as well as TRAP, telomere length, and luciferase promoter assays. Results: TERT promoter mutations were detected in 19 of 182 (10.4%) MPM cases and significantly associated with advanced disease and nonepithelioid histology. Mutations independently predicted shorter overall survival in both histologic MPM subtypes. Moreover, 9 of 9 (100%) mutated but only 13 of 36 (36.1%) wild-type samples formed immortalized cell lines. TERT promoter mutations were associated with enforced promoter activity and TERT mRNA expression, while neither telomerase activity nor telomere lengths were significantly altered. TERT promoter–mutated MPM cases exhibited distinctly reduced chromosomal alterations and specific mutation patterns. While BAP1 mutations/deletions were exclusive with TERT promoter mutations, homozygous deletions at the RBFOX1 and the GSTT1 loci were clearly enriched in mutated cases. Conclusions: TERT promoter mutations independently predict a dismal course of disease in human MPM. The altered genomic aberration pattern indicates that TERT promoter mutations identify a novel, highly aggressive MPM subtype presumably based on a specific malignant transformation process.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 27, No. 11 ( 2021-06-01), p. 3005-3016
    Abstract: The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth of distant metastases. In this study, pet dogs with appendicular osteosarcoma were leveraged as high-value biologic models for pediatric osteosarcoma, to assess mTOR inhibition as a therapeutic strategy for attenuating metastatic disease progression. Patients and Methods: A total of 324 pet dogs diagnosed with treatment-naïve appendicular osteosarcoma were randomized into a two-arm, multicenter, parallel superiority trial whereby dogs received amputation of the affected limb, followed by adjuvant carboplatin chemotherapy ± oral sirolimus therapy. The primary outcome measure was disease-free interval (DFI), as assessed by serial physical and radiologic detection of emergent macroscopic metastases; secondary outcomes included overall 1- and 2-year survival rates, and sirolimus pharmacokinetic variables and their correlative relationship to adverse events and clinical outcomes. Results: There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144–237] and 282 days (95% CI, 224–383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157–217) and 280 days (95% CI, 252–332), respectively. Conclusions: In a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2005
    In:  Clinical Cancer Research Vol. 11, No. 2 ( 2005-01-15), p. 594-599
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 11, No. 2 ( 2005-01-15), p. 594-599
    Abstract: Purpose: Matrix metalloproteinase (MMP) belongs to a large group of proteases capable of breaking essentially all components of the extracellular matrix. They are implicated in all steps of tumorogenesis, cancer invasion, and metastasis. Among them, metalloproteinase type 1 (MMP-1) is implicated in tumor invasion and metastasis in different types of cancers including colorectal cancer in which its expression was correlated with poor prognosis. A polymorphism in the promoter region of the MMP-1 gene leads to a variation of its level of transcription. Study Design: MMP-1 -1607ins/delG and MMP-3 - 1612 ins/delA promoter polymorphisms were genotyped by multiplex PCR from 201 colorectal cancer patients. The median follow-up of patients was 30 months. The MMP genotypes were correlated to clinical outcome. Results: Patients with the -1607insG/-1607insG MMP-1 genotype had significantly worse specific survival than the others in the whole series (P & lt; 0.04), in stage I to III patients (P & lt; 0.001), and in patients stage I and II (P & lt; 0.01). In multivariate analysis, MMP-1-1607insG allele showed to be an independent poor prognostic factor after adjustment on stage, age, and the use of adjuvant chemotherapy. MMP-3 polymorphism was not associated with survival. Conclusions: In the subgroups of nondistant metatastic patients (stages I and II, and stages I-III), an inverse relation between the number of MMP-1-1607insG allele and survival was observed suggesting a gene dosage effect. Our results are consistent with the importance of MMP-1-1607ins/delG functional polymorphism in regulating transcription level and with the relationship between MMP-1 expression and cancer invasion, metastasis, and prognosis.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2005
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2017
    In:  Cancer Research Vol. 77, No. 24 ( 2017-12-15), p. 6987-6998
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 24 ( 2017-12-15), p. 6987-6998
    Abstract: The PPARG gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. Cancer Res; 77(24); 6987–98. ©2017 AACR.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages